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Institute for Immunity & Transplantation, University College London Division of Infection & Immunity, Royal Free Campus, London,
NW3 2PF, UKThe mechanism of action of cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) remains surprisingly un-
clear. Regulatory T (Treg) cells can use CTLA-4 to elicit
suppression; however, CTLA-4 also operates in conven-
tional T cells, reputedly by triggering inhibitory signals.
Recently, interactions mediated via the CTLA-4 cyto-
plasmic domain have been shown to preferentially affect
Treg cells, yet other evidence suggests that the extracel-
lular domain of CTLA-4 is sufficient to elicit suppression.
Here, we discuss these paradoxical findings in the con-
text of CTLA-4-mediated ligand regulation. We propose
that the function of CTLA-4 cytoplasmic domain is not to
transmit inhibitory signals but to precisely control the
turnover, cellular location, and membrane delivery of
CTLA-4 to facilitate its central function: regulating the
access of CD28 to their shared ligands.
The need for CTLA-4-based regulation
The generation of a large repertoire of T cell receptors is
necessary to recognize a wide array of unknown pathogens
throughout our lives. However, this approach to immune
protection comes with drawbacks, most notably the need to
control self-reactive T cells that are generated during this
process. While the thymus provides some degree of selec-
tion against generation of self-reactive T cells, this process
is by necessity incomplete, and self-reactive T cells popu-
late our peripheral pool. CTLA-4 is a key player in the
control of such cells, and mice genetically deficient in
CTLA-4 have profound immune dysregulation and auto-
immune disease [1,2]. Interestingly, the major cell type
expressing CTLA-4 are Treg cells [3,4]. It is also clear that
CTLA-4 does not operate in isolation, but that it directly
antagonizes the costimulatory receptor CD28 (Figure 1).
Accordingly, the fatal autoimmunity observed in CTLA-4-
deficient mice is likely to be the result of excessive CD28
stimulation by its ligands CD80 and CD86. Indeed, block-
ade or deletion of either the ligands [5,6] or CD28 [7]
prevents autoimmunity triggered by the loss of CTLA-4.
Given that CTLA-4 binds the same ligands as CD28, but
with higher affinity, it is also apparent that the system
operates in an integrated fashion. Nonetheless, the1471-4906/
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tion have been widely debated. In this opinion article,
rather than comprehensively review the CTLA-4 field,
we consider some of the more recent findings in this area
in the context of the literature, and suggest a new frame-
work for their interpretation.
CTLA-4 inhibitory signals
How does CTLA-4 signal?
CTLA-4 has a 36-amino acid cytoplasmic tail that is devoid
of intrinsic enzymatic activity and lacks a bona fide ITIM
motif [8]. Unlike CD28, which is a surface receptor, CTLA-
4 is highly endocytic, spending much of its time in intra-
cellular vesicles (Box 1). It is constitutively present as a
homodimer [9] and does not appear to undergo conforma-
tional change following ligand binding [10,11]. Numerous
molecular interactions have been proposed to account for
CTLA-4 inhibitory signaling in T cells. It is common prac-
tice to simply list these pathways as though all are equally
validated, with their relative roles perhaps depending on
cellular context. Yet, in our view, it is perhaps surprising
that none of these proposed signaling pathways has been
reproducibly demonstrated to the point where they provide
anything approaching a robust platform, as has been
achieved for other important signaling receptors.
A survey of the literature in this area highlights multi-
ple contradictions. Some studies suggested that CTLA-4
altered phosphorylation of CD3z chains [12], but other
studies found this not to be the case [13]. CTLA-4 was
reported to disrupt the formation of ZAP-70 microclusters
[14]; however, others found that CTLA-4 function did not
interfere with ZAP-70 recruitment or phosphorylation
[13,15]. Some reports showed that CTLA-4 interacted with
phosphoinositide 3-kinase (PI3K) [16], although others
found that the CTLA-4 cytoplasmic tail was unable to
recruit this enzyme [17]. The tyrosine phosphatase SHP-
2 (SYP) was originally reported to bind specifically to the
tyrosine-phosphorylated YVKM sequence in the CTLA-4
cytoplasmic tail [18]; however, the requirement for tyro-
sine phosphorylation was later questioned [12]. Subse-
quent analysis concluded that there was not in fact a
direct interaction between CTLA-4 and SHP-2 [19] and
imaging approaches showed that neither SHP-1 nor SHP-2
were co-recruited with CTLA-4 to the immunological syn-
apse [20]. CTLA-4 was reported to increase AKT activity
[21], although others found decreased AKT activity follow-
ing CTLA-4 engagement [22]. Similar to CD28, CTLA-4
has been shown to associate with the serine/threonineTrends in Immunology, February 2015, Vol. 36, No. 2 63
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Figure 1. The CD28 and CTLA-4 receptors are connected by shared ligands. CD28
and CTLA-4 on the T cell bind to two ligands, CD80 and CD86, on antigen-presenting
cells (APCs). The interactions take place with varying affinities (represented by
thickness of the arrows). Given that CTLA-4 has higher affinity for both ligands, this
sets up a competition between CTLA-4 and CD28 for ligand binding. The system is
integrated in the sense that alteration of one component has the potential to affect
the equilibriumof the other interactions. For example, blockade or deletion of CTLA-4
will lead to increased availability of ligands for CD28 binding and vice versa.
Abbreviations: Tconv, conventional T cells; TCR, T cell receptor.
Box 1. CTLA-4 is a moving target
A key feature of CTLA-4 is its rapid and constitutive endocytosis from
the plasma membrane resulting in approximately 90% of CTLA-4
being intracellular. Yeast two-hybrid interaction analysis revealed
that the CTLA-4 cytoplasmic tail associates with the m2 subunit of the
adaptor complex AP-2 [89,90]. m2 is known to bind tyrosine-contain-
ing YXXfmotifs, where Y is tyrosine, X is any amino acid, and f is an
amino acidwith a bulky hydrophobic side chain, such as the Y201VKM
sequence in CTLA-4. Indeed, substitution of Y201 for phenylalanine
abolished the interaction with m2 and inhibited endocytosis of CTLA-
4 [89,90]. Strong evidence suggests that only the dephosphorylated
formof YVKM can bindm2 [89,91]. Collectively, these data formed the
basis of a model in which nonphosphorylated CTLA-4 was interna-
lized via its AP-2 association, whereas tyrosine phosphorylation
stabilized it at the surface, permitting ligand engagement and con-
sequent negative signals.
While this model is still widely accepted, several groups have
reported that CTLA-4 inhibitory function does not require its tyrosine
phosphorylation [92–94]. In addition, it is clear that primary human T
cells continue to endocytose CTLA-4 following activation [81]. Given
that CTLA-4 is reportedly phosphorylated by ZAP-70 or p56lck [91,92],
it would be predicated that TCR activation of T cells would trigger
CTLA-4 phosphorylation and surface retention. However, analysis of
CTLA-4 expression in activated T cells showed that it was still pre-
dominantly intracellular and rates of CTLA-4 endocytosis remained
high [81].
Given that early experiments relied on transfection of p56lck or
p59fyn [91,95] or pervanadate treatment [89,95], it is possible that
CTLA-4 remains largely dephosphorylated and, therefore, endocytic,
during physiological T cell activation.
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of this phosphatase was responsible for CTLA-4-dependent
AKT inhibition [22]. However, a CTLA-4 mutant lacking
PP2A-binding sites appeared to show increased inhibitory
function [24], suggesting that rather than eliciting CTLA-4
function, PP2A inhibited it.
We do not wish to discuss the findings of the above
studies in detail. Rather, our intention is to highlight the
conflicting nature of the literature, a fact frequently over-
looked by those who suggest that negative signaling is a
well-established paradigm. In our view, the favored ap-
proach of ascribing a long list of signaling mechanisms to
CTLA-4 belies the true lack of consensus and progress in
this area.
Missing in action: the elusive nature of CTLA-4 signaling
In addition to the lack of a detailed description of the
CTLA-4 signaling components themselves, we note an
increasing number of settings in which evidence of
CTLA-4 signals might be expected, yet is not seen. Experi-
ments attempting to identify the transcriptional response
to antibody engagement of CTLA-4 revealed only subtle
changes, mainly during the first 4 h of stimulation, a time-
frame in which CTLA-4 expression is known to be low
[25]. In Treg cells, which express the highest levels of
CTLA-4, the effects of CTLA-4 engagement on transcript
expression were described as ‘weak or inexistent’, while, by
contrast, CD28 ligation had a robust transcriptional foot-
print [25]. Gene expression studies have also been per-
formed usingCTLA-4-sufficient or CTLA-4-deficient T cells
isolated from bone marrow chimeric mice: these chimeras
are healthy and provide the opportunity to examine CTLA-
4-deficient T cells that have not been isolated from an
animal with lymphoproliferative disease. These studies64similarly failed to find evidence of suppressive signals in
CTLA-4-expressing cells; the difference in terms of tran-
scripts expressed in CTLA-4-deficient T cells, as compared
withwild type cells, was described as ‘minimal’ [26]. Allison
and colleagues used an adoptive transfer system to exam-
ine gene expression changes in CTLA-4-sufficient or
CTLA-4-deficient T cells responding to cognate antigen
in vivo [27]. Only ten independent genes were upregulated
(more than twofold) in CTLA-4-expressing cells compared
with their CTLA-4-deficient counterparts, one being
CTLA-4 itself [27]. The authors concluded that there
was ‘no obvious signature of active negative regulation’
in CTLA-4-bearing T cells.
Finally, an interesting study from Bluestone and col-
leagues examined a mouse expressing a mutant form of
CTLA-4 in which the tyrosine residue at position 201 in the
intracellular YVKM motif was replaced with valine
(Y201V), thereby preventing phosphorylation of this motif
[28]. One prediction of this experiment was that conven-
tional T cells from these animals would be unable to
transmit inhibitory signals via CTLA-4. While these mice
developed more severe experimental autoimmune enceph-
alomyelitis (EAE) following injection with MOG35-55 pep-
tide in complete Freund’s adjuvant (CFA) in conjunction
with pertussis toxin, on closer examination it became
apparent that this reflected a defect in the Treg rather
than the conventional T cell population. Accordingly, con-
ventional T cells from mice expressing Y201V-CTLA-4
were indistinguishable from wild type T cells in their
capacity to induce EAE upon adoptive transfer, whereas
Treg cells from these animals showed impaired disease
regulation. While this could reflect a role for CTLA-4 in
transducing activating signals in Treg cells, it provides
little support for an inhibitory signaling model.
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around recruitment of inhibitory apparatus by CTLA-4,
which interferes with T cell receptor (TCR) and/or CD28
signaling, thereby thwarting early T cell activation. Such a
concept is difficult to simply extend to Treg cells, given that
in Treg cells both TCR signaling and CTLA-4 are required
for suppression. Therefore, the function of CTLA-4 in Treg
cells demands a different paradigm.
PKC-h: a new player in CTLA-4 signaling?
Perhaps the most enticing recent data relating to the
concept of CTLA-4 signaling come from work performed
in the Altman laboratory showing that CTLA-4 associates
with the protein kinase C isoform PKC-h [29]. In these
studies, Kong et al. revealed a physical association between
CTLA-4 and PKC-h in Treg cells that is mediated by a
membrane-proximal lysine motif in the CTLA-4 cyto-
plasmic tail. Notably, the interaction did not involve other
motifs previously implicated in CTLA-4 signaling (e.g.,
YVKM). Importantly, Treg cells lacking PKC-h were de-
fective in their capacity to suppress homeostatic T cell
proliferation and antitumor responses.
Given the clear biochemical evidence of a molecular
interaction between CTLA-4 and PKC-h, at first sightBox 2. Are agonistic anti-CTLA-4 Abs a valid experimental
tool?
One significant pillar underpinning the concept of inhibitory signal-
ing relates to the use of ‘agonistic’ anti-CTLA-4 Abs. The evidence
that such Abs are indeed agonistic, and deliver inhibitory signals,
stems from the practice of bead-coating anti-CD3 and anti-CD28 Ab to
trigger T cell activation and cross-titrating anti-CTLA-4 Ab to identify
a point where the latter elicits ‘inhibition’ of the T cell response. There
are several potential issues with this approach. First, to some extent,
these experiments are self-fulfilling prophecies, in that the ratios of
Abs are chosen to give the desired result (i.e., lack of T cell prolifera-
tion). It is unlikely that these ratios in any way reflect the natural
balance between CD28 and CTLA-4 engagement that occurs upon
ligand binding in physiological settings. Indeed, the balance between
CD28 and CTLA-4 engagement is pre-set by the natural ligand affi-
nities and differs substantially between the two ligands [96]. A sec-
ond issue relates to the fact that bead coating of stimulatory and
inhibitory Abs can result in artifacts, whereby the inhibitory anti-
bodies outcompete the activating Abs. Such coating bias has been
reported for anti-CD3 Ab-driven T cell responses [97]. This issue is
particularly problematic when the expected effects of CTLA-4 ligation
are precisely mimicked by decreased CD3 or CD28 signaling. Thus,
the same outcome could be achieved by CTLA-4 inhibitory signaling
or by a decreased density of anti-CD3 or anti-CD28 Ab on the beads.
Notably, in many studies, the negative effects of ‘agonistic’ Ab are
seen early, frequently before CTLA-4 is detectable by flow cytometry.
This is typically explained by the possibility that CTLA-4 is function-
ally active while still being below our detection levels. While this is a
theoretical possibility, alternatives worthy of consideration are that
the antibody may nonspecifically disrupt early T cell activation, for
example by diminishing CD3/CD28 clustering or by disrupting nor-
mal behavior of CTLA-4 following its induction.
In our personal experience, data generated using ‘agonistic’ Abs
are simply not helpful in understanding CTLA-4 biology: predictions
based on such data do not hold when tested in other systems (e.g.,
experiments involving ligand-driven responses or CTLA-4 gene-de-
ficient mice). By contrast, disrupting CTLA-4 contact with its natural
ligands, using antagonistic antibodies, appears to be generally reli-
able. Therefore, we would urge considerable caution in interpreta-
tion of experiments based on the concept of agonistic Abs.these data might appear to breath further life into the
concept of CTLA-4 signaling. However, to our minds, it is
less clear that a signaling event (i.e., ligand-triggered
activation of a pathway) is occurring. Indeed, in hybridoma
cells, the association of phosphorylated PKC-hwith CTLA-
4 appeared equivalent regardless of anti-CD3/CD86-Fc
stimulation, suggesting that the association is constitutive
[29]. Moreover, experiments with antibody stimulation
(Box 2) only used anti-CD3 and anti-CTLA-4 together,
with no comparison made with anti-CD3 alone; thus, as
presented, there is no compelling evidence that a CTLA-4-
triggered signaling event has occurred. This interpretation
does not detract from the potential importance of the
CTLA-4/PKC-h interaction. Indeed, the authors showed
that this association mediates recruitment of a GIT2–
aPIX–PAK complex that could have a key role in promot-
ing cellular motility through focal adhesion disassembly
[29]. Consistent with this notion, Treg cells lacking PKC-h
interacted more strongly with antigen-presenting cells
(APC), and were less efficient at serially engaging APC
to elicit ligand downregulation (see below for discussion of
ligand downregulation). Interestingly, GIT proteins are
known to be involved in membrane recycling and endoso-
mal dynamics [30], and can exhibit ADP-ribosylation factor
GTPase-activating protein (ARF-GAP) activity towards
ARF-1 [30], which has previously been implicated in
CTLA-4 membrane transport [31]. aPIX is also implicated
in recruitment of Lymphocyte function-associated antigen
1 (LFA1) to the immune synapse [32], which could be
relevant given the importance of the LFA1/ICAM1 inter-
action in gluing Treg cells to their targets [33]. Thus, the
PKC-h interaction with CTLA-4 could have several inter-
esting roles in controllingCTLA-4 cell biology and function.
However, in our opinion, the data presented do not invoke,
or indeed provide support for, a ligand-driven inhibitory
signal.
Effects of CTLA-4 on motility
CTLA-4 has been proposed to increase T cell motility,
thereby limiting contact time between T cells and APC.
In this model, CTLA-4 ligation serves to reverse the ‘stop
signals’ induced by productive TCR engagement and,
therefore, to limit the formation of stable conjugates be-
tween T cells and APC [34]. In other words, it transmits a
signal that prevents TCR induced adhesion. Similarly, a
more recent study [35] concluded that CTLA-4 induced ‘go’
signals thatmake T cells moremotile. Miska et al. reported
that a blocking anti-CTLA-4 antibody (Ab) increased the
motility of CD4 T effector (Teff) and Treg cells, but de-
creased the motility of CD8 Teff cells [36]. Taken at face
value, this would suggest that CTLA-4 transmits a ‘go’
signal to increase motility in CD8 T cells but an ‘arrest’
signal in CD4 T cells. The latter is in contrast to the
findings of Schneider et al., who reported that CTLA-4
reversed the arrest signal in CD4 cells [34]. Furthermore,
Miska et al. reported that CTLA-4 exerted the same effects
on motility in CD4 Teff and CD4 Treg cells [36], whilst Lu
et al. have argued that the CTLA-4 mediated reverse stop
signal was largely limited to conventional T cells (Tconv)
and not Treg cells [37]. Other studies have failed to find a
role for CTLA-4 blockade in affecting T cell motility [38].65
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Figure 2. The various forms of ligand competition. The figure depicts three
variations on the theme of competition between CD28 and CTLA-4 for access to
ligand (drawn generically as CD80/86). (A) Activated T cells express both CD28 and
CTLA-4, establishing a cell intrinsic competition for ligand access. Note that
experiments from bone marrow chimeric mice suggest that this intrinsic role has a
relatively minor role on T cell function in vivo. Nonetheless, this form of competition
may have significant effects in some experimental settings. (B) Regulatory T cells
(Treg) expressing CTLA-4 contact antigen-presenting cells (APC) and physically
sequester ligands. This is a form of extrinsic ligand competition as well as cellular
competition, because both Treg and conventional T cells (Tconv) are competing for
the same APC simultaneously. (C) CTLA-4 removes ligands from the APC via
transendocytosis. This is a form of cell extrinsic competition that is spatially and
temporally separated from the activation of Tconv. In this model, CTLA-4-expressing
Treg continually interact with APCs, remove ligands, and then detach. The APC is
unable to provide CD28 costimulation until ligand re-expression occurs. Experiments
from bone marrow chimeric mice suggest that cell extrinsic functions provide the
major part of CTLA-4 function in vivo. Note that cell extrinsic regulation can be
carried out by Tconv aswell as by Treg, albeit with Treg having higher levels of CTLA-
4 and providing more robust regulation [27,84]. Abbreviations: DC, dendritic cell;
HLA, human leukocyte antigen; TCR, T cell receptor.
Opinion Trends in Immunology February 2015, Vol. 36, No. 2In a recent paper from the Allison laboratory, the
authors suggested that the effects of CTLA-4 Ab on T cell
motility is not due to signaling but rather to the physical
disruption of stable interactions between T cells and their
targets [39]. The effects of anti-CTLA-4 Ab on intratumoral
T cell motility required chronic treatment, leading the
authors to speculate that indirect mechanisms, such as
Treg cell depletion [40,41], may be contributing. Such a
notion is consistent with the increased Teff cell motility
observed after acute Treg cell depletion in one study
[36]. Given the integrated nature of the CD28/CTLA-4
pathway (Figure 1), perturbation of one player invariably
has an impact on the other components. Therefore, CTLA-4
blockade could alter T cell motility indirectly by augment-
ing CD28 stimulation. CD28 functions are good candidates
for affecting motility. For example, CD28-driven PI3K
activation has been shown to control T cell migration
[42], and recent data demonstrate a critical role for
CD28-driven activation of inducible T cell kinase (ITK)
in T cell motility and tissue infiltration [43]. ITK is known
to affect actin accumulation at the T cell–APC interface
[44], and a role for the CD28-driven actin reorganization
and T cell triggering is also emerging [45,46].
Thus, while CTLA-4 manipulation can alter T cell mo-
tility in certain settings, whether this involves intrinsic
‘stop’ or ‘go’ signals or whether the antibody works indi-
rectly (e.g., by augmenting CD28 signaling or depleting
and/or impairing Treg cells) is less certain. Critically, cell
intrinsic effects of CTLA-4 should be discernable in bone
marrow chimeric mice in which wild type and CTLA-4–/–
cells are mixed. Thus, changes in motility and function
involving an intrinsic signal through CTLA-4 would be
predicted to affect CTLA-4-sufficient cells in a manner not
observed for CTLA-4-deficient cells. The behavior of CTLA-
4+ and CTLA-4– cells in chimeric mice has been extensively
examined and such differences have not been observed
[47–50].
CTLA-4-mediated ligand downregulation
One area that has gathered considerable momentum in
recent years is the idea that Treg cells expressing CTLA-4
can downregulate CD80 and CD86 on APC [51–53]. Work
from the Sakaguchi group showed that Treg cells were able
to downregulate both CD80 and CD86 [but not CD40 or
MHC class II] on dendritic cells (DC) in a manner that was
adhesion dependent [33]: downregulation was blocked by
anti-CTLA-4 Ab and was abrogated if Treg cells were
deficient in CTLA-4 [54]. The downregulation of costimu-
latory ligands by Treg cells or, conversely, their increased
expression following Treg cell depletion, has been consis-
tently observed bymultiple groups both in vitro [55,56] and
in vivo [57–60], suggesting that it is a core feature of Treg
cell behavior. The use of CTLA-4 to remove ligands from
APC in a cell-extrinsic manner is essentially an extension
of the ability of CTLA-4 to compete with CD28 at the
immune synapse in a cell intrinsic manner (Figure 2)
[20,61].
We recently reported a mechanism that explains CTLA-
4-dependent ligand downregulation [62]. In this model,
CTLA-4 binds to, and physically removes, ligands from
APC by transendocytosis, targeting them for lysosomal66degradation. Intercellular transfer of proteins between
cells in the immune system is not uncommon [63] and
transendocytosis has previously been demonstrated for
notch ligands [64] and ephrin-Bs [65]. Importantly,
CTLA-4-mediated transendocytosis is driven by engage-
ment of the TCR. This simple mechanism fits well with the
known features of CTLA-4 cell biology as well as the TCR
Opinion Trends in Immunology February 2015, Vol. 36, No. 2dependence of Treg cell function. Based on this model, it is
possible to make several predictions concerning CTLA-4-
dependent regulation. Most obviously, ligand removal is
cell contact and time dependent (Hou and Sansom, unpub-
lished 2014). Moreover, the expression level of CTLA-4
relative to the expression of its ligands will control the
extent of downregulation. These quantitative consider-
ations provide a simple conceptual framework and raise
the notion of ‘efficiency’ in respect of CTLA-4-based ligand
downregulation. In this regard, it is interesting that Treg
cells lacking PKC-h were shown to have altered contact
time with APC in a manner that limited their capacity to
serially engage with cellular targets and achieve ligand
depletion [29]. The concept that Treg cells have higher-
affinity TCR recognition of self antigens [66,67] and show
more stable interactions with APC compared with Tconv
cells [33] is also consistent with them being well adapted to
carry out transendocytosis. Notably, regulating the level of
costimulatory molecules present on APCs would be a clear
explanation for the role of CTLA-4 in peripheral tolerance,
including in the linked suppression models studied by
Waldmann and colleagues [68].
Is the major role of the CTLA-4 cytoplasmic domain to
control cellular localization?
A surprising finding from several studies is that the extra-
cellular domain of CTLA-4 is sufficient for substantial
inhibitory function. Treg cells from CTLA-4–/– mice trans-
genically expressing only a membrane-anchored extracel-
lular domain of CTLA-4 suppressed T cell responses as
efficiently as those expressing wild type CTLA-4 [69]. Like-
wise, in other studies, expression of a tailless version of
CTLA-4 was sufficient to confer suppressive capacity
[70,71]. These data are in agreement with the original
demonstration that expression of a tailless CTLA-4 mole-
cule could prevent lethal pathology in CTLA-4–/– mice
[72]. Collectively these studies are consistent with a model
in which CTLA-4 can function without eliciting signal
transduction through its cytoplasmic tail. Thus, the extra-
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Figure 3. Identified cytoplasmic domain motifs involved in CTLA-4 trafficking and cell
shown in single-letter code. Reported motifs involved in cellular localization are shown i
domain but for which the specific motifs are not defined are shown in black. For defincellular domain of CTLA-4 is capable of substantial im-
mune regulation, albeit when overexpressed at the cell
surface, as is the case in these mutants.
How then can tailless CTLA-4 elicit suppressive func-
tion, yet CTLA-4 with amutated cytoplasmic tail [28] or an
inability to bind PKC-h [29] be impaired? We propose a
model in which suppressive function is mediated by the
extracellular domain of CTLA-4; however, the cytoplasmic
domain contributes to suppressive function by controlling
the quantity, cellular localization, and timing of CTLA-4
expression at the membrane. According to this model, the
role of the cytoplasmic domain is not to transmit inhibitory
signals, but rather to direct the appropriate trafficking of
the CTLA-4 molecule. In doing so, the cytoplasmic domain
becomes a keymodifier of the efficiency of CTLA-4 function.
The role of the cytoplasmic domain in regulating CTLA-
4 expression patterns is well known. Specifically, the tyro-
sine-based YVKM motif mediates rapid endocytosis from
the plasma membrane via interaction with the clathrin
adaptor activating protein 2 (AP-2; Box 1). Endocytosis
likely involves other motifs (Figure 3) because YVKM
mutants are not completely defective in endocytosis
[31,73,74]. Accordingly, the proline motif has been sug-
gested to also contribute to AP-2 binding [75] and the C-
terminal tyrosine sequence YFIPIN functions as an alter-
native (albeit weaker) endocytic adaptor [76]. AP-1 inter-
actions have been linked with CTLA-4 degradation [77],
while mutating the YVKM motif to YEKM has been sug-
gested to influence CTLA-4 recycling [74]. The cytoplasmic
domain of CTLA-4 reportedly controls its recruitment to
lipid rafts [78] as well as mediating interactions with the
scaffold proteins T cell receptor-interacting molecule
(TRIM) and linker for activation of X cells (LAX), which
influences CTLA-4 surface expression [79,80]. The recent
study by Kong et al. also suggests an important role for the
membrane proximal lysine motif in bringing CTLA-4 into
complex with PKC-h. Together, these data argue for a
sophisticated control of CTLA-4 expression that utilizes
a variety of motifs in the cytoplasmic domain.ular localization. The amino acid sequence of the CTLA-4 cytoplasmic domain is
n color, whereas associations and/or functions that require the CTLA-4 cytoplasmic
ition of abbreviations, please see main text.
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pattern is gradually emerging. Intracellular trafficking of
CTLA-4 to lysosomes is likely important in the degradation
of ligands that are captured by transendocytosis [81]. En-
docytosis may also be required to limit the amount of
CTLA-4 at the plasma membrane, thereby allowing suffi-
cient CD28 engagement, which is important for Treg cell
homeostasis. The PKCeta interactions are also consistent
with the positional control of CTLA-4 within focal contacts
andwith effects on Treg cell adhesion. The rapid delivery of
CTLA-4 to the synapse following TCR signaling is facili-
tated by the existence of an intracellular pool that can be
quickly mobilized, similarly to some cytokines and CTL
granules [82,83]. Thus, it is clear that the cytoplasmic
domain controls the amount, timing, and fate of CTLA-4
that comes to the cell surface and that quantitative altera-
tions in these parameters can affect function. Accordingly,
while the ectodomain is ultimately responsible for CTLA-4
function, the cytoplasmic domain contains the controls.
Concluding remarks
The debate over the molecular mechanism of CTLA-4
function is now well into its second decade. While inhibi-
tory signaling has been a favored theme throughout this
time, in our opinion there is still little cohesive evidence for
such a pathway.Meanwhile, the growing appreciation that
a major role of CTLA-4 is in Treg cells has emphasized the
importance of alternative mechanisms of CTLA-4 function.
This has resulted in something of a hybrid model, where it
is argued that CTLA-4 mediates inhibitory signaling in
Tconv cells but then behaves differently in Treg cells.
While it is possible that CTLA-4 performs different
functions in different lymphocyte subsets, our view is that
there is no compelling evidence for this, neither is there a
need to invoke such a model. Imaging experiments have
shown that cell intrinsic competition between CD28 and
CTLA-4, based on affinity for ligands at the immune
synapse, can operate in both Treg andTconv cells [20]. Sim-
ilarly, transendocytosis of ligands can be mediated by both
Tconv and Treg cells [62], and it has been shown that in
vivo CTLA-4 can function in a cell extrinsic manner in
Tconv as well as Treg [27,84]. Moreover, CTLA-4 is capable
of conferring suppressive function in the absence of fork-
head box P3 (Foxp3) [85], and unconventional regulatory T
cells that lack Foxp3 have been shown to downregulate
ligands on DC in a CTLA-4-dependent manner [86]. Thus,
ligand downregulation appears to be a hard-wired function
of CTLA-4 regardless of cell type. Therefore, postulating
fundamentally different functions for CTLA-4 in Treg and
Tconv cells is unnecessary in our view. We propose that
control of CD28 access to its ligands is likely to be the
major, if not sole, function of CTLA-4. Given the increasing
manipulation of the CD28/CTLA-4 system therapeutically,
the need for clear and predictive models of CTLA-4 func-
tion is pressing, and important beyond simple academic
interest.
One consequence of a ligand competition model is that
quantitative efficiency becomes a key concept. A clear
prediction of this model is that there will be settings where
CTLA-4 is present and competes for ligand, yet has little or
no influence on the ensuing T cell response. For example, in68situations where there are large numbers of APCs expres-
sing high amounts of ligand, CTLA-4 competition is nu-
merically overwhelmed. A corollary of this concept is that
changes in parameters that affect efficiency of CTLA-4
competition, such as cellular adhesion, dwell time,
CTLA-4 recycling efficiency, and affinity for ligand, will
affect the degree of CTLA-4-based regulation. Therefore,
the ‘window’ of effective CTLA-4 control may shift follow-
ing changes to the cytoplasmic tail, and yet the ectodomain
alone may also appear completely effective in certain set-
tings. In short, there is no absolute measure of CTLA-4
function. If 10% CTLA-4 efficiency is sufficient to control a
given response, the function of a CTLA-4 mutant may
appear intact. Conversely, if 70% efficiency is required
to control a given response, a mutant with 60% efficiency
will appear defective. This may explain why CTLA-4 mole-
cules with mutated cytoplasmic domains can appear either
defective or intact, depending on the context. This quanti-
tative issue is amply demonstrated by the observation that
foundermice bearing the sameCTLA-4mutation exhibited
differing levels of CTLA-4-dependent control that correlat-
ed with expression level of the transgene [72].
Consistent with this concept, we and others have re-
cently found that heterozygous mutations in human
CTLA-4 can also lead to quantitative defects in regulation
and the emergence of an immune dysregulation syndrome
[87,88]. In our opinion, there is sufficient evidence to
consider moving away from signaling concepts towards a
quantitative model of ligand competition. We believe that
this will act as a more robust framework for interpreting
the impact of naturally arising mutations, which are in-
creasingly likely to be identified as a result of next-gener-
ation sequencing programmes.
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